CytomX Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $31,869 | $(569) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Amortization of intangible assets | 146 | 146 |
| Depreciation and amortization | 1,622 | 2,029 |
| Impairment loss on machinery and equipment | 106 | — |
| Accretion of discounts on short-term investments | (5,311) | (7,419) |
| Stock-based compensation expense | 7,668 | 8,558 |
| Non-cash lease expense | 4,084 | 3,729 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 329 | 32,554 |
| Prepaid expenses and other assets | 1,433 | 2,415 |
| Accounts payable | (297) | (1,426) |
| Accrued liabilities and other long-term liabilities | (9,628) | (7,041) |
| Deferred revenue | (118,252) | (89,011) |
| Net cash used in operating activities | $(86,231) | $(56,035) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (310) | (840) |
| Purchases of short term investments | (155,490) | (424,834) |
| Maturities of short term investments | 255,500 | 275,000 |
| Net cash provided by (used in) investing activities | $99,700 | $(150,674) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost | — | 29,669 |
| Proceeds from issuance of common stock, net of issuance cost | 6,909 | |
| Proceeds from employee stock purchase plan and exercise of stock options | 613 | 561 |
| Net cash provided by financing activities | $7,522 | $30,230 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 20,991 | (176,479) |
| Cash, cash equivalents and restricted cash, beginning of year | 18,088 | 194,567 |
| Cash, cash equivalents and restricted cash, end of year | $39,079 | $18,088 |
| Supplemental disclosures of noncash investing items: | ||
| Purchases of property and equipment in accounts payable and accrued liabilities | $8 | $75 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.